Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2006-04-18
2006-04-18
Wilson, James O. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093710, C424S577000, C435S325000, C435S385000, C435S386000, C514S024000
Reexamination Certificate
active
07029671
ABSTRACT:
The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(α-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.
REFERENCES:
patent: WO 93/05055 (1992-04-01), None
O'Doherty, U. et al “Dendritic cells freshly isolated from human blood . . . ” J. Exp. Med. vol. 178, pp. 1067-1078, 1993.
Grabbe et al., “Dendritic Cells As Initiators Of Tumor Immune Response: A Possible Strategy For Tumor Immunotherapy”,Immunology Today,Elsevier Science Ltd., vol. 16(3):117-121, (1995).
M. Crowley et al., “The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus1.”, Cellular Immunology, 118, pp. 108-125, 1989.
Kayo Inaba et al., “Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.”, J. Exp. Med., vol. 176, pp. 1693-1702, 1992.
Margit D. Witmer-Pack et al., “Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal langerhans cells.”, J. Exp. Med., vol. 166, pp. 1484-1498, 1987.
Christina M. Celluzzi et al., “Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity.”, J. Exp. Med., vol.. 183, pp. 283-287, 1996.
Paola Paglia et al., “Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.”, J. Exp. Med., vol. 183, pp. 317-322, 1996.
Frank J. Hsu et al., “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.”, Nature Medicine, vol. 2, No. 1, pp. 52-58, 1996.
Frederica Sallusto et al., “Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α.”, J. Exp. Med., vol. 179, pp. 1109-1118, 1994.
Frances Santiago-Schwartz et al., “TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages.”, Journal of Leukocyte Biology, vol. 52, pp. 274-281, 1992.
C. Caux et al., “GM-CSF and TNF—α cooperate in the generatio of dendritic langerhans cells.”, Nature, vol. 360, pp. 258-261, 1992.
Lars Svennerholm et al., “Sphingolipids of human skeletal muscle.”, Biochimica et Biophysica Acta, vol. 280, pp. 626-636, 1972.
K. A. Karlsson et al., “The sphingolipid composition of bovine kidney cortex, medulla and papilla.”, Biochimica et Biophysica Acta, vol. 316, pp. 317-335, 1973.
Masahiro Morita et al., “Structure-activity relationship of α-galactosylceramides against B16-bearing mice.”, J. Med. Chem. vol. 38, pp. 2176-2187, 1995.
Kazuhiro Motoki et al., “Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties.”, Biol. Pharm. Bull., vol. 18, No. 11, pp. 1487-1491, 1995.
Kazuhiro Motoki et al., “Radioprotective effects of α-galactosylceramides.”, Bioorganic & Medicinal Chemistry Letters, vol. 5, No. 20, pp. 2413-2416, 1995.
Kazuhiro Motoki et al., “Effects of α-galactosylceramides on bone marrow cells in vitro and hematopoiesis in vivo.”, Biol. Pharm. Bull. vol. 19, No. 7, pp. 952-955, 1996.
Y. Koezuka et al., “KRN7000, A novel enhancer of antigen presenting cell (APC) activity of dendritic cell (DC).”, The 9thInternational Congress of Immunology, p. 55, Abstract No. 324, 1995.
Yasunori Yamaguchi et al., “Enhancing effects of (2S, 3S, 4R)-1-0-(α-D-Galactopyranosyl)-2-(N-Hexacosanoylamino)-1, 3,4-Octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells.”, Oncology Research, vol. 8, Nos. 10/11, pp. 399-407, 1996.
Koezuka Yasuhiko
Motoki Kazuhiro
Yamaguchi Yasunori
Foley & Lardner
Kirin Brewery Company Limited
Maier Leigh C.
Wilson James O.
LandOfFree
Method for activating human antigen-presenting cells,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for activating human antigen-presenting cells,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for activating human antigen-presenting cells,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3616848